Stereotaxis (STXS) investor relations material

Company overview and business model

• Designs, manufactures, and markets robotic systems and instruments for interventional labs, focusing on Robotic Magnetic Navigation for endovascular interventions, especially cardiac ablation procedures for arrhythmias.

• Expanding clinical focus to coronary, neuro, and peripheral interventions, targeting a multi-billion-dollar medical device market with long-term growth potential.

• Products include Genesis RMN and GenesisX RMN Systems, Odyssey and Synchrony & SynX Solutions, and various branded interventional devices.

• Strategic relationships with technology leaders enable bundled offerings and compatibility with x-ray and mapping systems, critical for commercialization.

• Revenue model includes upfront capital payments for equipment and recurring payments for disposables, service, and software updates.

Financial performance and metrics

• As of February 28, 2026, 97,248,936 shares of common stock were outstanding, held by approximately 387 stockholders.

• Net tangible book value as of December 31, 2025, was $3.3 million ($0.04 per share); after the offering, as adjusted, $51.7 million ($0.42 per share).

• Immediate dilution to new investors is estimated at $1.46 per share based on an assumed offering price of $1.88.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for working capital, research and development, general corporate purposes, and accelerated commercialization of the innovation pipeline.

• Management retains broad discretion over allocation and timing of expenditures.

• Proceeds may be temporarily invested in short-term marketable securities or used to repay short-term debt.